4.57Open5.30Pre Close29 Volume1.35K Open Interest20.00Strike Price15.68KTurnover474.31%IV18.69%PremiumJan 17, 2025Expiry Date2.29Intrinsic Value100Multiplier10DDays to Expiry3.31Extrinsic Value100Contract SizeAmericanOptions Type-0.4057Delta0.0279Gamma2.55Leverage Ratio-0.2761Theta-0.0035Rho-1.03Eff Leverage0.0114Vega
Jasper Therapeutics Stock Discussion
Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria
14 of 15 participants enrolled achieved a clinical response
10 of 12 participants in the 120mg cohort achieved a complete response
No serious adverse events; no grade 3 or higher adverse events reported
Initial data from BEACON study expected week of January 6th, 2025, including 180mg Q8W cohort
Company to host conference call and webinar today at 8:00 ...
Microsoft $Microsoft (MSFT.US)$ (office currently has nearly 400 million users, OficARPU increases after the acquisition of OpenA and Azurez-related...
No comment yet